AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve clinical remission over a full year when used as a maintenance therapy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,